Risankizumab (BI 655066) is a humanized IgG monoclonal antibody that specifically targets the p19 subunit of interleukin-23 (IL-23), exhibiting a high binding affinity with a dissociation constant (Kd) of less than 10 pM. This antibody effectively inhibits the production of interleukin-17 (IL-17) induced by IL-23 in mouse splenocytes, demonstrating a half-maximal inhibitory concentration (IC50) of 2 pM. Risankizumab is primarily utilized in research focused on immunological and inflammatory disorders, including psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis, providing a valuable tool for understanding the pathophysiology and potential therapeutic interventions for these conditions.
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody that specifically targets the p19 subunit of interleukin-23 (IL-23), exhibiting a high binding affinity with a dissociation constant (Kd) of less than 10 pM. This antibody effectively inhibits the production of interleukin-17 (IL-17) induced by IL-23 in mouse splenocytes, demonstrating a half-maximal inhibitory concentration (IC50) of 2 pM. Risankizumab is primarily utilized in research focused on immunological and inflammatory disorders, including psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis, providing a valuable tool for understanding the pathophysiology and potential therapeutic interventions for these conditions.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
